Published in AIDS Weekly, March 6th, 2000
The company's new HIV Emergency Treatment IND application is intended to be used to study the effects of Ampligen on the growing number of people with AIDS who are developing resistance to their currently approved regimens, some of whom have been left with no other clinical options. Hemispherx's Phase II and Phase III trials are intended to study the effects of Ampligen in combination with several Highly Active Antiretroviral Therapy (HAART) regimens, which have been structured by Anderson Clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.